title: Effects of erythropoietin administration on blood pressure and urinary albumin excretion in rats.
abstract: The effects of recombinant human erythropoietin (rHuEPO) administration on blood pressure and urinary albumin excretion were studied in normotensive Wistar-Kyoto rats (WKY), in spontaneously hypertensive rats (SHR), and in SHR rats treated with an angiotensin converting enzyme inhibitor (SHR-ACEi). Rats were housed in metabolic cages and treated with rHuEPO (150 U/kg body weight [bw] three times a week) for 6 weeks. Control animals received the vehicle only (0.25 mL of physiological saline). An angiotensin converting enzyme inhibitor was administered in the drinking water for 6 weeks (spirapril 5 mg/kg bw). Systolic blood pressure (SBP), and 24 h urinary albumin excretion (UAE) were measured once a week. No significant differences in SBP were observed between rHuEPO and vehicle-treated normotensive animals at the end of the treatment (171.9 +/- 4.9 v 172.1 +/- 5.6 mm Hg, respectively). After 6 weeks, SBP was significantly higher in SHR and SHR-ACEi groups treated with rHuEPO than in control groups (239.8 +/- 7.3 and 243.0 +/- 7.3 mm Hg v 218.1 +/- 6.0 and 187.9 +/- 4.6 mm Hg, respectively); UAE was significantly higher in groups treated with rHuEPO than in control groups (WKY: 265.9 +/- 19.5 v 127.0 +/- 12.3 microg/100 g bw, SHR: 1668.4 +/- 564.6 v 234.8 +/- 22.9 microg/100 g bw, and SHR-ACEi: 1522.7 +/- 448.3 v 143.0 +/- 18.9 microg/100 g bw, respectively). We concluded that erythropoietin treatment causes an increase in arterial pressure in SHR only, and an increase in UAE in both normotensive and hypertensive rats. The albuminuric effect was not entirely dependent on increased blood pressure. The treatment with an angiotensin converting enzyme inhibitor did not modify either the proteinuric or the pressor effects.
authors.affiliation: Istituto di Clinica Medica Generale e Terapia Medica, University of Milan, Ospedale Maggiore, Milano, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Panzacchi
authors.forename: F
authors.initials: F
authors.lastname: Pieruzzi
authors.forename: G
authors.initials: G
authors.lastname: Castoldi
authors.forename: G
authors.initials: G
authors.lastname: Busca
authors.forename: G B
authors.initials: GB
authors.lastname: Bolla
authors.forename: G
authors.initials: G
authors.lastname: Buccianti
authors.forename: F
authors.initials: F
authors.lastname: Radice
authors.forename: C
authors.initials: C
authors.lastname: Fava
authors.forename: I
authors.initials: I
authors.lastname: Martini
authors.forename: A
authors.initials: A
authors.lastname: Zanchetti
authors.forename: R
authors.initials: R
authors.lastname: Golin
authors.forename: A
authors.initials: A
authors.lastname: Stella
mesh_terms: D000419:Albuminuria / Q000378:metabolism*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D004326:Drinking; D004921:Erythropoietin / Q000494:pharmacology*; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D011994:Recombinant Proteins; D012964:Sodium / Q000652:urine; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D012964:Sodium